1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Astellas Pharma said on December 1 that the US FDA accepted for priority review a combination of its antibody drug conjugate Padcev (enfortumab vedotin) and Merck’s PD-1 inhibitor Keytruda (pembrolizumab) as a first-line therapy for locally advanced or metastatic urothelial…
To read the full story
Related Article
- Padcev-Keytruda Approved in Europe for 1st Line Bladder Cancer
August 29, 2024
- Padcev-Keytruda Nears EU Nod for 1st Line Bladder Cancer
July 30, 2024
- Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Keytruda/Padcev Filed in Japan for 1st Line Bladder Cancer Treatment: MSD, Astellas
February 1, 2024
- Astellas/Pfizer Seeks 1st Line Bladder Cancer Use for Padcev/Keytruda in EU
January 30, 2024
- Padcev/Keytruda Combo Nabs FDA Nod for 1st Line Bladder Cancer
December 19, 2023
- Padcev/Keytruda Combo Wins US Accelerated Nod for First-Line Bladder Cancer: Astellas
April 5, 2023
BUSINESS
- LTL Pharma Sees 30% Drop in Gaster Sales after New LLP Coverage Rollout
February 19, 2025
- CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
- Kyorin Nabs Japan Option for Cyrano’s Post-Viral Smell Loss Drug
February 19, 2025
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…